Previous close | 25.60 |
Open | 26.01 |
Bid | 25.78 x 100 |
Ask | 25.85 x 200 |
Day's range | 25.68 - 26.22 |
52-week range | 23.14 - 35.56 |
Volume | |
Avg. volume | 495,320 |
Market cap | 1.218B |
Beta (5Y monthly) | 1.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.00 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 48.91 |
FOSTER CITY, Calif., May 01, 2024--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress.
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.